Ireland - English - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - amlodipine; valsartan - film-coated tablet - 10 mg/320 milligram(s) - valsartan and amlodipine

Ireland - English - HPRA (Health Products Regulatory Authority)

rowex ltd - amlodipine; valsartan - film-coated tablet - 5mg/80 milligram(s) - angiotensin ii antagonists and calcium channel blockers; valsartan and amlodipine

Ireland - English - HPRA (Health Products Regulatory Authority)

rowex ltd - amlodipine; valsartan - film-coated tablet - 5mg/160 milligram(s) - angiotensin ii antagonists and calcium channel blockers; valsartan and amlodipine

Ireland - English - HPRA (Health Products Regulatory Authority)

rowex ltd - amlodipine; valsartan - film-coated tablet - 10mg/160 milligram(s) - angiotensin ii antagonists and calcium channel blockers; valsartan and amlodipine

Ireland - English - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - amlodipine; valsartan - film-coated tablet - 5/80 milligram(s) - angiotensin ii antagonists and calcium channel blockers; valsartan and amlodipine

Ireland - English - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - amlodipine; valsartan - film-coated tablet - 5/160 milligram(s) - angiotensin ii antagonists and calcium channel blockers; valsartan and amlodipine

Ireland - English - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - amlodipine; valsartan - film-coated tablet - 10/160 milligram(s) - angiotensin ii antagonists and calcium channel blockers; valsartan and amlodipine

Ireland - English - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - amlodipine; valsartan - film-coated tablet - 5 mg/80 milligram(s) - hmg coa reductase inhibitors, other combinations; zzz rosuvastatin and amlodipine

United States - English - NLM (National Library of Medicine)

strides pharma science limited - amlodipine besylate (unii: 864v2q084h) (amlodipine - unii:1j444qc288), valsartan (unii: 80m03yxj7i) (valsartan - unii:80m03yxj7i), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - amlodipine/valsartan/hydrochlorothiazide is indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including amlodipine, hydrochlorothiazide, and the arb class to which valsartan principally belongs. there are no controlled trials demonstrating risk reduction with amlodipine/valsartan/hydrochlorothiazide. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education p

United States - English - NLM (National Library of Medicine)

golden state medical supply, inc. - amlodipine besylate (unii: 864v2q084h) (amlodipine - unii:1j444qc288), valsartan (unii: 80m03yxj7i) (valsartan - unii:80m03yxj7i), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - amlodipine/valsartan/hydrochlorothiazide is indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including amlodipine, hydrochlorothiazide, and the arb class to which valsartan principally belongs. there are no controlled trials demonstrating risk reduction with amlodipine/valsartan/hydrochlorothiazide. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education p